United States · FDA
FDA approval not reviewed here
Alzheimer’s disease
See FDA labeling for the approved population and indication; this page covers the trial population only.
Loading research and source information…
Alzheimer’s disease · Drug research
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Evidence 1Content updated Nov 17, 2026 · Sources last checked Nov 17, 2026
Inclusion Criteria * Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach. * Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening. * Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities. * Participants on acetyl choline esterase inhibitors (AChEIs) and/or memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration. Exclusion Criteria * Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment, urinary retention, active biliary disease, moderate-severe renal impairment (eGFR of \<50 mL/min), and unstable hypertension or tachycardia. * Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion. * Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening. * Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that reflect significant pathology other than AD or could affect safety or interfere with study procedures. * Other protocol-defined Inclusion/Exclusion criteria apply.
This record covers only the linked trial population. This registry-based page does not review FDA approval or labeling.
FDA approval not reviewed here
Alzheimer’s disease
See FDA labeling for the approved population and indication; this page covers the trial population only.
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
registry · NCT06976216 · Structured source fields
Source date: Oct 27, 2026 · Checked: Nov 3, 2026
Evidence location: protocolSection: identificationModule, statusModule, conditionsModule, armsInterventionsModule, designModule, outcomesModule, eligibilityModule, contactsLocationsModule, sponsorCollaboratorsModule; hasResults
Status: RECRUITING. Phase: PHASE3. Conditions: Alzheimer's Disease.
Open original sourceA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
registry · NCT06976216 · Structured source fields
Source date: Oct 27, 2026 · Checked: Nov 16, 2026
Evidence location: protocolSection: identificationModule, statusModule, conditionsModule, armsInterventionsModule, designModule, outcomesModule, eligibilityModule, contactsLocationsModule, sponsorCollaboratorsModule; hasResults
Status: RECRUITING. Phase: PHASE3. Conditions: Alzheimer's Disease.
Open original sourceA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
registry · NCT06976216 · Structured source fields
Source date: Nov 17, 2026 · Checked: Nov 17, 2026
Evidence location: protocolSection: identificationModule, statusModule, conditionsModule, armsInterventionsModule, designModule, outcomesModule, eligibilityModule, contactsLocationsModule, sponsorCollaboratorsModule; hasResults
Status: RECRUITING. Phase: PHASE3. Conditions: Alzheimer's Disease.
FDA labeling has not been reviewed for this page. This does not mean the treatment is unapproved.
Approval is specific to the indication and population. It does not establish availability, reimbursement or suitability for an individual.
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted resultsStudy ages: 60 Years to 85 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Argentina, Australia, Brazil, Canada, Chile, Croatia, Czechia, France, Germany, Greece, India, Italy, Netherlands, Poland, Puerto Rico, Romania, South Korea, Spain, United States.
Sites marked recruiting: Argentina, Australia, Brazil, Canada, Chile, Croatia, Czechia, France, Germany, Greece, Italy, Netherlands, Poland, Puerto Rico, Romania, South Korea, Spain, United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: Sep 11, 2028 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1registry · Registry metadata is submitted by the sponsor or responsible party and does not independently validate efficacy.
No posted registry results are indicated in this source response. This does not establish that no results exist elsewhere.
Limitations: Outcomes, effect estimates, uncertainty and study quality have not been appraised. Consult original results and publications.
Evidence 1